Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients

Renal Failure

Volumn 26, Issue 3, 2004, Pages 289-295

  Lin, Chun Liang ^a   Hung, Cheng Chieh ^a   Yang, Cheng Ta ^a   Huang, Chiu Ching ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anemia; Erythropoietin (EPO); Hemodialysis (HD); Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; FERRITIN; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; INTERMETHOD COMPARISON; KIDNEY FAILURE; LONG TERM CARE; LONGITUDINAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT FAILURE; TREATMENT OUTCOME;

ANEMIA; CALCITRIOL; CASE-CONTROL STUDIES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROIDECTOMY; RENAL DIALYSIS;

EID: 3943098702     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120039528     Document Type: Article

References (13)

1. Drucke, T.B. Modulating factors in the hematopoietic response to erythropoietin. Am. J. Kidney Dis. Oct 1991, 18 (4 Suppl 1), 87-92.
2. Danielson, B. R-HuEPO hyporesponsiveness-who and why? Nephrol. Dial. Transplant. 1995, 10 (Suppl 2), 69-73.
3. European Erythropoietin Symposium: Moving into the Second Decade of Clinical Experience in CRF. Seville, Spain, 11-13 November 1994. Nephrol. Dial. Transplant. 1995, 10 (Suppl 2), 1-109.
4. Drueke, T.B. R-HuEPO hyporesponsiveness-who and why? Nephrol. Dial. Transplant. 1995, 10 Suppl 2, 62-68.
5. Yasunaga, C.; Matsuo, K.; Yanagida, T.; Matsuo, S.; Nakamoto, M.; Goya, T. Early effects of parathyroidectomy on erythropoietin production in secondary hyperparathyroidism. Am. J. Surg. Feb 2002, 183 (2), 199-204.
6. Goicoechea, M.; Vazquez, M.I.; Ruiz, M.A.; Gomez-Campdera, F.; Perez-Garcia, R.; Valderrabano, F. Intravenous calcitriol improves anemia and reduces the need for erythropoietin in hemodialysis patients. Nephron 1998, 78 (1), 23-27.
7. Drueke, T.B.; Eckardt, K.U. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol. Dial. Transplant. 2002, 17 (Suppl 5), 28-31.
8. Sunder-Plassmann, G.; Horl, W.H. Novel aspects of erythropoietin response in renal failure patients. Nephrol. Dial. Transplant. 2001, 16 (Suppl 5), 40-44.
9. Eckardt, K.U. Pathophysiology of renal anemia. Clin. Nephrol. Feb 2000, 53 (1 Suppl.), S2-S8.
10. Aucella, F.; Gatta, G.; Vigilante, M.; Scalzulli, R.P.; Mantuano, S.; Carotenuto, M.; Stallone, C. Calcitriol increases burst forming unit-erythroid (BFU-E) in vitro proliferation in chronic uremia. Synergic effect with DNA recombinant erythropoietin (rHu-Epo). Minerva Urol. Nefrol. Mar 2001, 53(1), 1-5.
11. Llach, F.; Hervas, J.; Cerezo, S. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am. J. Kidney Dis. Nov 1995, 26 (5), 845-851.
12. Mandolfo, S.; Malberti, F.; Farina, M.; Villa, G.; Scanziani, R.; Surian, M.; Imbasciati, E. Parathyroidectomy and response to erythropoietin therapy in anemic patients with chronic renal failure. Nephrol. Dial. Transplant. Oct 1998, 13 (10), 2708-2709.
13. Nomura, S.; Ogawa, Y.; Osawa, G.; Katagiri, M.; Harada, T.; Nagahana, H. Myelofibrosis secondary to renal osteodystrophy. Nephron 1996, 72 (4), 683-687.